{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:04:53Z","timestamp":1780074293909,"version":"3.54.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000052","name":"U.S. Department of Health & Human Services | NIH | NIH Office of the Director","doi-asserted-by":"publisher","award":["U42OD035738"],"award-info":[{"award-number":["U42OD035738"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"U.S. Department of Health & Human Services | NIH | NIH Office of the Director","doi-asserted-by":"publisher","award":["U42OD027090"],"award-info":[{"award-number":["U42OD027090"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"U.S. Department of Health & Human Services | NIH | NIH Office of the Director","doi-asserted-by":"publisher","award":["U42OD035738"],"award-info":[{"award-number":["U42OD035738"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"U.S. Department of Health & Human Services | NIH | NIH Office of the Director","doi-asserted-by":"publisher","award":["U42OD027090"],"award-info":[{"award-number":["U42OD027090"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Use of adeno-associated virus (AAV) vectors has revolutionized in vivo gene therapy, but the presence of pre-existing neutralizing antibodies remains a major barrier that can hinder clinical application. While large-animal models such as non-human primates have been used to study anti-AAV immunity, their high cost and limited accessibility present challenges for studying the impact of AAV immunity on AAV-based therapies. Here, we evaluate pigs as an immunologically relevant large-animal model for investigating humoral barriers to AAV-based gene therapy. Using ELISA-based profiling across 11 AAV serotypes, we detected immunoglobulin G (IgG) antibodies against AAV capsids in pigs as early as two weeks of age, with titers increasing with age and displaying serotype-specific dynamics. Animals maintained in standard housing displayed greater inter-individual variations and broader serotype-specific reactivities. Functional assays demonstrated that these antibodies neutralized AAV particles in a dose- and serotype-dependent manner, with IgG depletion restoring transduction in vitro. Sequence analysis indicated that capsid identity can partially predict cross-reactive binding, but only under controlled conditions. These findings establish pigs as a tunable model capable of recapitulating age- and environment-dependent features of anti-AAV immunity, providing a platform for studying humoral barriers and evaluating immune evasion strategies in AAV-based gene therapy.<\/jats:p>","DOI":"10.1038\/s41434-026-00625-1","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T16:29:55Z","timestamp":1780072195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Environmental and developmental factors shape anti-AAV immunity in pigs"],"prefix":"10.1038","author":[{"given":"Godwin I.","family":"Iroanya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilangovan","family":"Raju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra","family":"Boosani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep N.","family":"Subramanyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6329-0322","authenticated-orcid":false,"given":"Addison K.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4968-8187","authenticated-orcid":false,"given":"Jonathan A.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"625_CR1","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358\u201378. https:\/\/doi.org\/10.1038\/s41573-019-0012-9.","journal-title":"Nat Rev Drug Discov"},{"key":"625_CR2","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrg3742","volume":"15","author":"MA Kotterman","year":"2014","unstructured":"Kotterman MA, Schaffer DV. Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet. 2014;15:445\u201351.","journal-title":"Nat Rev Genet"},{"key":"625_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","volume":"21","author":"C Li","year":"2020","unstructured":"Li C, Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet. 2020;21:255\u201372. https:\/\/doi.org\/10.1038\/s41576-019-0205-4.","journal-title":"Nat Rev Genet"},{"key":"625_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11095-018-2564-5","volume":"36","author":"T Ong","year":"2019","unstructured":"Ong T, Pennesi ME, Birch DG, Lam BL, Tsang SH. Adeno-associated viral gene therapy for inherited retinal disease. Pharmacol Res. 2019;36:34. https:\/\/doi.org\/10.1007\/s11095-018-2564-5.","journal-title":"Pharmacol Res"},{"key":"625_CR5","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713\u201322.","journal-title":"N Engl J Med"},{"key":"625_CR6","first-page":"2670","volume":"99","author":"JD Mount","year":"2002","unstructured":"Mount JD, Herzog RW, Tillson DM, Goodman SA, Robinson N, McCleland ML, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood J Am Soc Hematol. 2002;99:2670\u20136.","journal-title":"Blood J Am Soc Hematol"},{"key":"625_CR7","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1056\/NEJMoa2414783","volume":"392","author":"UM Reiss","year":"2025","unstructured":"Reiss UM, Davidoff AM, Tuddenham EGD, Chowdary P, McIntosh J, Muczynski V, et al. Sustained CLINICAL benefit of AAV gene therapy in severe hemophilia B. N Engl J Med. 2025;392:2226\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2414783.","journal-title":"N Engl J Med"},{"key":"625_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/gt.2015.109","volume":"23","author":"B Greenberg","year":"2016","unstructured":"Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Pogoda JM, et al. Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure. Gene Ther. 2016;23:313\u20139. https:\/\/doi.org\/10.1038\/gt.2015.109.","journal-title":"Gene Ther"},{"key":"625_CR9","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1089\/hum.2009.182","volume":"21","author":"S Boutin","year":"2010","unstructured":"Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010;21:704\u201312.","journal-title":"Hum Gene Ther"},{"key":"625_CR10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1086\/595830","volume":"199","author":"R Calcedo","year":"2009","unstructured":"Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. 2009;199:381\u201390. https:\/\/doi.org\/10.1086\/595830.","journal-title":"J Infect Dis"},{"key":"625_CR11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1089\/hum.2021.287","volume":"33","author":"R Klamroth","year":"2022","unstructured":"Klamroth R, Hayes G, Andreeva T, Gregg K, Suzuki T, Mitha IH, et al. Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia A. Hum Gene Ther. 2022;33:432. https:\/\/doi.org\/10.1089\/hum.2021.287.","journal-title":"Hum Gene Ther"},{"key":"625_CR12","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1089\/hum.2011.031","volume":"22","author":"L Wang","year":"2011","unstructured":"Wang L, Calcedo R, Bell P, Lin J, Grant RL, Siegel DL, et al. Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther. 2011;22:1389\u2013401.","journal-title":"Hum Gene Ther"},{"key":"625_CR13","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1089\/hum.2024.079","volume":"35","author":"X Qin","year":"2024","unstructured":"Qin X, Li H, Zhao H, Xiang K, Liu S, Lou R, et al. Prevalence of neutralizing antibodies against AAV serotypes 2 and 9 in healthy participants from multiple centers across China and patients with DMD\/BMD. Hum Gene Ther. 2024;35:969\u201377. https:\/\/doi.org\/10.1089\/hum.2024.079.","journal-title":"Hum Gene Ther"},{"key":"625_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1089\/hum.2018.098","volume":"30","author":"DP Perocheau","year":"2019","unstructured":"Perocheau DP, Cunningham SC, Lee J, Antinao Diaz J, Waddington SN, Gilmour K, et al. Age-related seroprevalence of antibodies against AAV-LK03 in a UK population cohort. Hum Gene Ther. 2019;30:79\u201387. https:\/\/doi.org\/10.1089\/hum.2018.098.","journal-title":"Hum Gene Ther"},{"key":"625_CR15","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1093\/infdis\/jit319","volume":"208","author":"MA Brehm","year":"2013","unstructured":"Brehm MA, Shultz LD, Luban J, Greiner DL. Overcoming current limitations in humanized mouse research. J Infect Dis. 2013;208:S125\u201330. https:\/\/doi.org\/10.1093\/infdis\/jit319.","journal-title":"J Infect Dis"},{"key":"625_CR16","doi-asserted-by":"publisher","unstructured":"Bennett RS, Huzella LM, Jahrling PB, Bollinger L, Olinger GG, Hensley LE. Nonhuman primate models of Ebola virus disease. In: M\u00fchlberger E, Hensley LL, Towner JS, editors. Marburg- and Ebolaviruses. Cham: Springer International Publishing; 2017. p. 171\u201393. Available from: http:\/\/link.springer.com\/10.1007\/82_2017_20. https:\/\/doi.org\/10.1007\/82_2017_20","DOI":"10.1007\/82_2017_20"},{"key":"625_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s12026-011-8243-9","volume":"51","author":"R Vuyyuru","year":"2011","unstructured":"Vuyyuru R, Patton J, Manser T. Human immune system mice: current potential and limitations for translational research on human antibody responses. Immunol Res. 2011;51:257\u201366. https:\/\/doi.org\/10.1007\/s12026-011-8243-9.","journal-title":"Immunol Res"},{"key":"625_CR18","doi-asserted-by":"crossref","unstructured":"Ramos K, Downey A, Yost O. Nonhuman primate models in biomedical research: state of the science and future needs. The National Academies Press; 2023. Available from: https:\/\/nap.nationalacademies.org\/catalog\/26857\/nonhuman-primate-models-in-biomedical-research-state-of-the-science","DOI":"10.17226\/26857"},{"key":"625_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/ani9010012","volume":"9","author":"C Carvalho","year":"2018","unstructured":"Carvalho C, Gaspar A, Knight A, Vicente L. Ethical and scientific pitfalls concerning laboratory research with non-human primates, and possible solutions. Animals. 2018;9:12. https:\/\/doi.org\/10.3390\/ani9010012.","journal-title":"Animals"},{"key":"625_CR20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00441-020-03206-9","volume":"380","author":"R Pabst","year":"2020","unstructured":"Pabst R. The pig as a model for immunology research. Cell Tissue Res. 2020;380:287\u2013304. https:\/\/doi.org\/10.1007\/s00441-020-03206-9.","journal-title":"Cell Tissue Res"},{"key":"625_CR21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41684-024-01377-4","volume":"53","author":"H Jia","year":"2024","unstructured":"Jia H, Chang Y, Song J. The pig as an optimal animal model for cardiovascular research. Lab Anim. 2024;53:136\u201347. https:\/\/doi.org\/10.1038\/s41684-024-01377-4.","journal-title":"Lab Anim"},{"key":"625_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/ame2.12223","volume":"5","author":"N Hou","year":"2022","unstructured":"Hou N, Du X, Wu S. Advances in pig models of human diseases. Anim Model Exp Med. 2022;5:141\u201352. https:\/\/doi.org\/10.1002\/ame2.12223.","journal-title":"Anim Model Exp Med"},{"key":"625_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.prevetmed.2021.105358","volume":"191","author":"BH Hayes","year":"2021","unstructured":"Hayes BH, Andraud M, Salazar LG, Rose N, Vergne T. Mechanistic modeling of African swine fever: a systematic review. Prevent Vet Med. 2021;191:105358. https:\/\/doi.org\/10.1016\/j.prevetmed.2021.105358.","journal-title":"Prevent Vet Med"},{"key":"625_CR24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1089\/hum.2021.213","volume":"33","author":"Y Dai","year":"2022","unstructured":"Dai Y, Kavita U, Lampen MH, Gielen S, Banks G, Levesque P, et al. Prevalence of pre-existing neutralizing antibodies against adeno-associated virus serotypes 1, 2, 5, 6, 8, and 9 in sera of different pig strains. Hum Gene Ther. 2022;33:451\u20139. https:\/\/doi.org\/10.1089\/hum.2021.213.","journal-title":"Hum Gene Ther"},{"key":"625_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2018.03.004","volume":"342","author":"C Leborgne","year":"2019","unstructured":"Leborgne C, Latournerie V, Boutin S, Desgue D, Qu\u00e9r\u00e9 A, Pignot E, et al. Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients. Cell Immunol. 2019;342. 103780.","journal-title":"Cell Immunol"},{"key":"625_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1450858","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X, Klann PJ, Wiedtke E, Sano Y, Fischer N, Schiller L, et al. Seroprevalence of binding and neutralizing antibodies against 18 adeno-associated virus types in patients with neuromuscular disorders. Front Immunol. 2024;15. 1450858. https:\/\/doi.org\/10.3389\/fimmu.2024.1450858.","journal-title":"Front Immunol"},{"key":"625_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1089\/hum.2023.117","volume":"35","author":"C Wei","year":"2024","unstructured":"Wei C, Li D, Zhang M, Zhao Y, Liu Y, Fan Y, et al. Prevalence of adeno-associated virus-9-neutralizing antibody in chinese patients with Duchenne muscular dystrophy. Hum Gene Ther. 2024;35:26\u201335. https:\/\/doi.org\/10.1089\/hum.2023.117.","journal-title":"Hum Gene Ther"},{"key":"625_CR28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.dci.2008.06.016","volume":"33","author":"HJ Rothk\u00f6tter","year":"2009","unstructured":"Rothk\u00f6tter HJ. Anatomical particularities of the porcine immune system\u2014a physician\u2019s view. Dev Comp Immunol. 2009;33:267\u201372. https:\/\/doi.org\/10.1016\/j.dci.2008.06.016.","journal-title":"Dev Comp Immunol"},{"key":"625_CR29","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.dci.2008.07.011","volume":"33","author":"M \u0160inkora","year":"2009","unstructured":"\u0160inkora M, Butler JE. The ontogeny of the porcine immune system. Dev Comp Immunol. 2009;33:273\u201383. https:\/\/doi.org\/10.1016\/j.dci.2008.07.011.","journal-title":"Dev Comp Immunol"},{"key":"625_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12026-007-0062-7","volume":"39","author":"JE Butler","year":"2007","unstructured":"Butler JE, Sinkora M. The isolator piglet: a model for studying the development of adaptive immunity. Immunol Res. 2007;39:33\u201351. https:\/\/doi.org\/10.1007\/s12026-007-0062-7.","journal-title":"Immunol Res"},{"key":"625_CR31","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3389\/fimmu.2013.00341","volume":"4","author":"R Calcedo","year":"2013","unstructured":"Calcedo R, Wilson JM. Humoral Immune Response to AAV. Front Immunol. 2013;4:341. https:\/\/doi.org\/10.3389\/fimmu.2013.00341","journal-title":"Front Immunol"},{"key":"625_CR32","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.vaccine.2020.12.049","volume":"40","author":"M Albrecht","year":"2022","unstructured":"Albrecht M, Pagenkemper M, Wiessner C, Spohn M, L\u00fctgehetmann M, Jacobsen H, et al. Infant immunity against viral infections is advanced by the placenta-dependent vertical transfer of maternal antibodies. Vaccine. 2022;40:1563\u201371. https:\/\/doi.org\/10.1016\/j.vaccine.2020.12.049.","journal-title":"Vaccine"},{"key":"625_CR33","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41591-019-0392-8","volume":"25","author":"C Pou","year":"2019","unstructured":"Pou C, Nkulikiyimfura D, Henckel E, Olin A, Lakshmikanth T, Mikes J, et al. The repertoire of maternal anti-viral antibodies in human newborns. Nat Med. 2019;25:591\u20136. https:\/\/doi.org\/10.1038\/s41591-019-0392-8.","journal-title":"Nat Med"},{"key":"625_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0301-6226(02)00182-3","volume":"78","author":"JA Rooke","year":"2002","unstructured":"Rooke JA, Bland IM. The acquisition of passive immunity in the newborn piglet. Livest Prod Sci. 2002;78:13\u201323. https:\/\/doi.org\/10.1016\/S0301-6226(02)00182-3.","journal-title":"Livest Prod Sci"},{"key":"625_CR35","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.dci.2008.07.007","volume":"33","author":"H Salmon","year":"2009","unstructured":"Salmon H, Berri M, Gerdts V, Meurens F. Humoral and cellular factors of maternal immunity in swine. Dev Comp Immunol. 2009;33:384\u201393. https:\/\/doi.org\/10.1016\/j.dci.2008.07.007. Mar 1.","journal-title":"Dev Comp Immunol"},{"key":"625_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-20082-1","volume":"12","author":"SS Maciag","year":"2022","unstructured":"Maciag SS, Bellaver FV, Bombassaro G, Haach V, Mor\u00e9s MAZ, Baron LF, et al. On the influence of the source of porcine colostrum in the development of early immune ontogeny in piglets. Sci Rep. 2022;12:15630. https:\/\/doi.org\/10.1038\/s41598-022-20082-1.","journal-title":"Sci Rep"},{"key":"625_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.101117","volume":"31","author":"JW Day","year":"2023","unstructured":"Day JW, Mendell JR, Burghes AHM, van Olden RW, Adhikary RR, Dilly KW. Adeno-associated virus serotype 9 antibody seroprevalence for patients in the United States with spinal muscular atrophy. Mol Ther Methods Clin Dev. 2023;31:101117. https:\/\/doi.org\/10.1016\/j.omtm.2023.101117.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"625_CR38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1089\/humc.2016.048","volume":"27","author":"R Calcedo","year":"2016","unstructured":"Calcedo R, Wilson JM. AAV natural infection induces broad cross-neutralizing antibody responses to multiple AAV serotypes in chimpanzees. Hum Gene Ther Clin Dev. 2016;27:79\u201382. https:\/\/doi.org\/10.1089\/humc.2016.048.","journal-title":"Hum Gene Ther Clin Dev"},{"key":"625_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fimmu.2014.00009","volume":"5","author":"YS Tseng","year":"2014","unstructured":"Tseng YS, Agbandje-McKenna M. Mapping the AAV capsid host antibody response toward the development of second-generation gene delivery vectors. Front Immunol. 2014;5:9.","journal-title":"Front Immunol"},{"key":"625_CR40","doi-asserted-by":"publisher","first-page":"9111","DOI":"10.1128\/jvi.00622-13","volume":"87","author":"BL Gurda","year":"2013","unstructured":"Gurda BL, DiMattia MA, Miller EB, Bennett A, McKenna R, Weichert WS, et al. Capsid antibodies to different adeno-associated virus serotypes bind common regions. J Virol. 2013;87:9111\u201324. https:\/\/doi.org\/10.1128\/jvi.00622-13.","journal-title":"J Virol"},{"key":"625_CR41","doi-asserted-by":"publisher","first-page":"9281","DOI":"10.1128\/jvi.74.19.9281-9293.2000","volume":"74","author":"CE Wobus","year":"2000","unstructured":"Wobus CE, H\u00fcgle-D\u00f6rr B, Girod A, Petersen G, Hallek M, Kleinschmidt JA. Monoclonal antibodies against the adeno-associated virus type 2 (aav-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2\u2013cell interaction and neutralization of AAV-2 infection. J Virol. 2000;74:9281\u201393. https:\/\/doi.org\/10.1128\/jvi.74.19.9281-9293.2000.","journal-title":"J Virol"},{"key":"625_CR42","doi-asserted-by":"publisher","unstructured":"Agbandje-McKenna M, Kleinschmidt J. AAV capsid structure and cell interactions. In: Snyder RO, Moullier P, editors. Adeno-associated virus: methods and protocols. Totowa: Humana Press; 2011. p. 47\u201392. Available from: https:\/\/doi.org\/10.1007\/978-1-61779-370-7_3","DOI":"10.1007\/978-1-61779-370-7_3"},{"key":"625_CR43","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01681-24","volume":"98","author":"SK Powell","year":"2024","unstructured":"Powell SK, McCown TJ. Adeno-associated virus 9 (AAV9) viral proteins VP1, VP2, and membrane-associated accessory protein (MAAP) differentially influence in vivo transgene expression. J Virol. 2024;98:e01681-24. https:\/\/doi.org\/10.1128\/jvi.01681-24.","journal-title":"J Virol"},{"key":"625_CR44","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","volume":"122","author":"F Mingozzi","year":"2013","unstructured":"Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood. 2013;122:23\u201336. https:\/\/doi.org\/10.1182\/blood-2013-01-306647.","journal-title":"Blood"},{"key":"625_CR45","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01251-21","volume":"96","author":"SN Emmanuel","year":"2022","unstructured":"Emmanuel SN, Smith JK, Hsi J, Tseng YS, Kaplan M, Mietzsch M, et al. Structurally mapping antigenic epitopes of adeno-associated virus 9: development of antibody escape variants. J Virol. 2022;96:e01251. https:\/\/doi.org\/10.1128\/JVI.01251-21.","journal-title":"J Virol"},{"key":"625_CR46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/hgtb.2012.243","volume":"24","author":"VL Jeune","year":"2013","unstructured":"Jeune VL, Joergensen JA, Hajjar RJ, Weber T. Pre-existing anti\u2013adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods. 2013;24:59\u201367. https:\/\/doi.org\/10.1089\/hgtb.2012.243.","journal-title":"Hum Gene Ther Methods"},{"key":"625_CR47","doi-asserted-by":"publisher","first-page":"11854","DOI":"10.1073\/pnas.182412299","volume":"99","author":"GP Gao","year":"2002","unstructured":"Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA. 2002;99:11854\u20139. https:\/\/doi.org\/10.1073\/pnas.182412299.","journal-title":"Proc Natl Acad Sci USA"},{"key":"625_CR48","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/mt.2011.177","volume":"20","author":"K Rapti","year":"2012","unstructured":"Rapti K, Louis-Jeune V, Kohlbrenner E, Ishikawa K, Ladage D, Zolotukhin S, et al. Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol Ther. 2012;20:73\u201383. https:\/\/doi.org\/10.1038\/mt.2011.177","journal-title":"Mol Ther"},{"key":"625_CR49","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1038\/mt.2010.175","volume":"18","author":"GD Hurlbut","year":"2010","unstructured":"Hurlbut GD, Ziegler RJ, Nietupski JB, Foley JW, Woodworth LA, Meyers E, et al. Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy. Mol Ther. 2010;18:1983\u201394. https:\/\/doi.org\/10.1038\/mt.2010.175.","journal-title":"Mol Ther"},{"key":"625_CR50","doi-asserted-by":"publisher","unstructured":"Elmore ZC, Oh DK, Simon KE, Fanous MM, Asokan A. Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme. JCI Insight. 5:e139881. https:\/\/doi.org\/10.1172\/jci.insight.139881","DOI":"10.1172\/jci.insight.139881"},{"key":"625_CR51","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1016\/j.ymthe.2024.05.004","volume":"32","author":"TJ Smith","year":"2024","unstructured":"Smith TJ, Elmore ZC, Fusco RM, Hull JA, Rosales A, Martinez M, et al. Engineered IgM and IgG cleaving enzymes for mitigating antibody neutralization and complement activation in AAV gene transfer. Mol Ther. 2024;32:2080\u201393. https:\/\/doi.org\/10.1016\/j.ymthe.2024.05.004.","journal-title":"Mol Ther"},{"key":"625_CR52","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/SLA.0000000000002924","volume":"268","author":"BE Lonze","year":"2018","unstructured":"Lonze BE, Tatapudi VS, Weldon EP, Min ES, Ali NM, Deterville CL, et al. IdeS (Imlifidase): a novel agent that cleaves human IgG and permits successful kidney transplantation across high-strength donor-specific antibody. Ann Surg. 2018;268:488\u201396.","journal-title":"Ann Surg"},{"key":"625_CR53","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1177\/10430342251378524","volume":"36","author":"GI Iroanya","year":"2025","unstructured":"Iroanya GI, Subramanyam PN, Wells KD, Green JA. Pre-existing anti-adeno-associated virus immunity in gene therapy: mechanisms, challenges, and potential solutions. Hum Gene Ther. 2025;36:1463\u201380. https:\/\/doi.org\/10.1177\/10430342251378524.","journal-title":"Hum Gene Ther"},{"key":"625_CR54","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1089\/hum.2023.194","volume":"35","author":"E Kropf","year":"2024","unstructured":"Kropf E, Markusic DM, Majowicz A, Mingozzi F, Kuranda K. Complement system response to adeno-associated virus vector gene therapy. Hum Gene Ther. 2024;35:425\u201338. https:\/\/doi.org\/10.1089\/hum.2023.194.","journal-title":"Hum Gene Ther"},{"key":"625_CR55","doi-asserted-by":"publisher","first-page":"11567","DOI":"10.1128\/JVI.05859-11","volume":"85","author":"MR Vogt","year":"2011","unstructured":"Vogt MR, Dowd KA, Engle M, Tesh RB, Johnson S, Pierson TC, et al. Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms. J Virol. 2011;85:11567\u201380. https:\/\/doi.org\/10.1128\/JVI.05859-11.","journal-title":"J Virol"},{"key":"625_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.999021","volume":"13","author":"CJ Smith","year":"2022","unstructured":"Smith CJ, Ross N, Kamal A, Kim KY, Kropf E, Deschatelets P, et al. Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood. Front Immunol. 2022;13:999021. https:\/\/doi.org\/10.3389\/fimmu.2022.999021.","journal-title":"Front Immunol"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00625-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00625-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00625-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T16:29:57Z","timestamp":1780072197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00625-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":56,"alternative-id":["625"],"URL":"https:\/\/doi.org\/10.1038\/s41434-026-00625-1","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal procedures were conducted in accordance with institutional and federal guidelines for the care and use of laboratory animals. The study was approved by the University of Missouri Institutional Animal Care and Use Committee. Animals were housed under controlled environmental conditions with ad libitum access to food and water. All blood collections were performed by trained personnel, and all efforts were made to minimize animal handling and discomfort.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}